Cargando…
Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer, with a 5-year survival rate of less than 20%. N6-methyladenosine (m(6)A) is the most prevalent RNA epigenetic modification in eukaryotic cells, and post-transcriptionally regulates gene expression and function by affecting RNA m...
Autores principales: | Chen, Yaxin, Xia, Lei, Peng, Yuxuan, Wang, Gang, Bi, Liyun, Xiao, Xue, Li, Cui, Li, Weimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593055/ https://www.ncbi.nlm.nih.gov/pubmed/36303829 http://dx.doi.org/10.3389/fonc.2022.947808 |
Ejemplares similares
-
Corrigendum: Development and validation of a m(6)A -regulated prognostic signature in lung adenocarcinoma
por: Chen, Yaxin, et al.
Publicado: (2023) -
Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies
por: Xue, Liang, et al.
Publicado: (2020) -
Constructing and validating of m6a-related genes prognostic signature for stomach adenocarcinoma and immune infiltration: Potential biomarkers for predicting the overall survival
por: Yang, Jing, et al.
Publicado: (2022) -
Development and Validation of Prognostic Model for Lung Adenocarcinoma Patients Based on m6A Methylation Related Transcriptomics
por: Li, Huijun, et al.
Publicado: (2022) -
Identification and validation of m6A-GPI signatures as a novel prognostic model for colorectal cancer
por: Ma, Bin, et al.
Publicado: (2023)